Atezolizumab in NSCLC: Push the Positive, Bury the Negative?

Recently published conclusions from the first interim analysis of overall survival in the IMpower010 trial of adjuvantAt a median follow-up of 45.3 months, 127 of 507 patients in the atezolizumab group and 124 of 498 in the best supportive care group had died.

In a subgroup of 476 patients with tumor PD-L1 expression ≥1%, patients who received atezolizumab exhibited a nonsignificant 29% improvement in overall survival . The best results were in the subgroup of 229 patients with tumor PD-L1 expression ≥50% ― these patients exhibited a 57% improvement in overall survival with atezolizumab . Those with PD-L1 expression 1% to 49%, however, demonstrated no improvement in overall survival ., H.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Cryptocurrency back in spotlight in legislative push from CongressIt was a big week for cryptocurrency on Capitol Hill, with the House moving forward with a couple major pieces of legislation and a bipartisan caste of senators planning an even more aggressive bill.
Source: dcexaminer - 🏆 6. / 94 Read more »

South Korean dog meat farmers push back against growing moves to outlaw their industryDog meat consumption, a centuries-old practice on the Korean Peninsula, isn't explicitly prohibited or legalized in South Korea. But more and more people want it banned, and there's increasing public awareness of animal rights and worries about South Korea’s international image.
Source: AP - 🏆 728. / 51 Read more »